Suppr超能文献

靶向KRAS突变型非小细胞肺癌：挑战与机遇

Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.

作者信息

Zhang Jun, Park Dongkyoo, Shin Dong M, Deng Xingming

机构信息

Department of Hematology and Medical Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA Department of Internal Medicine, Division of Hematology, Oncology and Blood & Marrow Transplantation, Holden Comprehensive Cancer Center, University of Iowa Carver College of Medicine, Iowa City, IA 52242, USA.

Department of Radiation Oncology, Emory University School of Medicine and Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA.

出版信息

Acta Biochim Biophys Sin (Shanghai). 2016 Jan;48(1):11-6. doi: 10.1093/abbs/gmv118. Epub 2015 Nov 17.

DOI:10.1093/abbs/gmv118
PMID:26578706
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4689161/
Abstract

Oncogenic mutations in Kirsten rat sarcoma viral oncogene homolog (KRAS) occur in 15%-30% of non-small cell lung cancer (NSCLC). However, despite decades of intensive research, there is still no direct KRAS inhibitor with clinically proven efficacy. Considering its association with poor treatment response and prognosis of lung cancer, developing an effective inhibitory approach is urgently needed. Here, we review different strategies currently being explored to target KRAS-mutant NSCLC, discuss opportunities and challenges, and also propose some novel methods and concepts with the promise of clinical application.

摘要

Kirsten大鼠肉瘤病毒癌基因同源物（KRAS）的致癌突变发生在15%-30%的非小细胞肺癌（NSCLC）中。然而，尽管经过数十年的深入研究，目前仍没有经临床验证有效的直接KRAS抑制剂。鉴于其与肺癌治疗反应不佳和预后不良相关，迫切需要开发一种有效的抑制方法。在此，我们综述了目前正在探索的针对KRAS突变型NSCLC的不同策略，讨论了机遇和挑战，并提出了一些有望应用于临床的新方法和概念。

相似文献

1
Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.
Acta Biochim Biophys Sin (Shanghai). 2016 Jan;48(1):11-6. doi: 10.1093/abbs/gmv118. Epub 2015 Nov 17.
2
Targeting Mutant Non-Small-Cell Lung Cancer: Past, Present and Future.
Int J Mol Sci. 2020 Jun 17;21(12):4325. doi: 10.3390/ijms21124325.
3
Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Cancer. 2019 Apr 1;125(7):1038-1049. doi: 10.1002/cncr.31871. Epub 2018 Dec 11.
4
Metabolic rewiring in mutant Kras lung cancer.
FEBS J. 2018 Jan;285(1):28-41. doi: 10.1111/febs.14125. Epub 2017 Jun 22.
5
microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.
Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):14924-9. doi: 10.1073/pnas.1520329112. Epub 2015 Nov 16.
6
Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.
Oncotarget. 2017 Jan 3;8(1):179-190. doi: 10.18632/oncotarget.10162.
7
Current Approaches in NSCLC Targeting K-RAS and EGFR.
Int J Mol Sci. 2019 Nov 14;20(22):5701. doi: 10.3390/ijms20225701.
8
Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis.
Sci Signal. 2020 Mar 3;13(621):eaax2364. doi: 10.1126/scisignal.aax2364.
9
Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.
Expert Rev Respir Med. 2016;10(1):53-68. doi: 10.1586/17476348.2016.1115349. Epub 2015 Nov 17.
10
Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma.
Cell Commun Signal. 2019 Oct 28;17(1):137. doi: 10.1186/s12964-019-0446-z.

引用本文的文献

1
The current landscape of using direct inhibitors to target KRAS-mutated NSCLC.
Exp Hematol Oncol. 2023 Nov 4;12(1):93. doi: 10.1186/s40164-023-00453-8.
2
Does Molecular Profiling of -Mutant Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Help in Treatment Strategy Planning?
Curr Oncol. 2022 Jul 7;29(7):4779-4790. doi: 10.3390/curroncol29070379.
3
SREBP1 regulates mitochondrial metabolism in oncogenic KRAS expressing NSCLC.
FASEB J. 2020 Aug;34(8):10574-10589. doi: 10.1096/fj.202000052R. Epub 2020 Jun 22.
4
Chromosomal instability suppresses the growth of K-Ras-induced lung adenomas.
Cell Cycle. 2019 Aug;18(15):1702-1713. doi: 10.1080/15384101.2019.1629790. Epub 2019 Jun 24.
5
KRAS status is related to histological phenotype in gastric cancer: results from a large multicentre study.
Gastric Cancer. 2019 Nov;22(6):1193-1203. doi: 10.1007/s10120-019-00972-6. Epub 2019 May 20.
6
Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.
Mol Cancer. 2019 Apr 10;18(1):85. doi: 10.1186/s12943-019-1012-4.
7
Targeting DNA Double-Strand Break Repair Pathways to Improve Radiotherapy Response.
Genes (Basel). 2019 Jan 4;10(1):25. doi: 10.3390/genes10010025.
8
Implications of KRAS mutations in acquired resistance to treatment in NSCLC.
Oncotarget. 2017 Dec 21;9(5):6630-6643. doi: 10.18632/oncotarget.23553. eCollection 2018 Jan 19.
9
KRAS induces lung tumorigenesis through microRNAs modulation.
Cell Death Dis. 2018 Feb 13;9(2):219. doi: 10.1038/s41419-017-0243-9.

本文引用的文献

1
Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
J Thorac Oncol. 2015 Sep;10(9):1319-1327. doi: 10.1097/JTO.0000000000000607.
2
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.
Br J Clin Pharmacol. 2015 Nov;80(5):1139-48. doi: 10.1111/bcp.12688. Epub 2015 Jul 22.
3
Enhancing FTS (Salirasib) efficiency via combinatorial treatment.
Biol Cell. 2015 May;107(5):130-43. doi: 10.1111/boc.201400087. Epub 2015 Apr 21.
4
Non-small cell lung cancer, version 1.2015.
J Natl Compr Canc Netw. 2014 Dec;12(12):1738-61. doi: 10.6004/jnccn.2014.0176.
5
Targeting RAS-ERK signalling in cancer: promises and challenges.
Nat Rev Drug Discov. 2014 Dec;13(12):928-42. doi: 10.1038/nrd4281.
6
BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Invest New Drugs. 2015 Feb;33(1):12-21. doi: 10.1007/s10637-014-0163-9. Epub 2014 Oct 25.
7
Drugging the undruggable RAS: Mission possible?
Nat Rev Drug Discov. 2014 Nov;13(11):828-51. doi: 10.1038/nrd4389. Epub 2014 Oct 17.
8
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
N Engl J Med. 2014 Nov 13;371(20):1867-76. doi: 10.1056/NEJMoa1408868. Epub 2014 Sep 29.
9
The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma.
Blood. 2014 Oct 2;124(14):2190-5. doi: 10.1182/blood-2014-03-559963. Epub 2014 Jul 29.
10
Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
J Exp Clin Cancer Res. 2014 Jun 17;33(1):52. doi: 10.1186/1756-9966-33-52.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验